Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728780 · ClinicalTrials.gov registry record · Phase 1
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.
A Phase 1 study of Adverse Events and Pharmacokinetic Variables, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00728780 is a Phase 1 study of Adverse Events and Pharmacokinetic Variables that has completed, run by AstraZeneca. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00728780, a Phase 1 study of Adverse Events and Pharmacokinetic Variables, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.
Conditions Studied
Interventions
- DRUG ABT-143
- DRUG ABT-335 and rosuvastatin
Study Locations (1)
Indiana
- Site Reference ID/Investigator# 11101 - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728780
The ClinicalTrials.gov registry entry for NCT00728780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adverse Events appearing as the primary indexed condition, and to 2 interventions - of which ABT-143 is the first listed.
NCT00728780 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00728780 about?
NCT00728780 is a clinical study titled "Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.". The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.
What is the current status of trial NCT00728780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-08.
What conditions does trial NCT00728780 study?
This clinical trial studies the following conditions: Adverse Events, Pharmacokinetic Variables.
What interventions are being tested in trial NCT00728780?
The interventions under investigation include: ABT-143 (DRUG), ABT-335 and rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00728780?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00728780 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Events
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.